Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignancy with a marked racial and geographic distribution. Specifically, it is highly prevalent in southern China, Southeast Asia, and the Middle East. It differs significantly from other squamous cell cancers of the head and neck in its clinical presentation, epidemiology, biological behavior, treatment, and prognosis. The five year survival rate of advanced NPC treated with Intensity Modulated Radiotherapy has reached up to 83.3% but not satisfactory. So the early detection of initial and recurrent NPC is important to an earlier therapy and improved outcome. Read more..